Clinical Trial Update: Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating beta-1,3/1,6-D-Glucan from Ganoderma lucidum as an adjuvant therapy for cardiometabolic syndrome; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiometabolic Syndrome

Drugs mentioned

• Polysaccharide peptide from Ganoderma lucidum (beta-1,3/1,6-D-Glucan) (beta-1,3/1,6-D-Glucan from Ganoderma lucidum polysaccharide peptide)

Snippet

Sponsor: University of Brawijaya | Conditions: Cardiometabolic Syndrome | Phase 2 | Status: UNKNOWN